DBV Technologies SA
PAR:DBV

Watchlist Manager
DBV Technologies SA Logo
DBV Technologies SA
PAR:DBV
Watchlist
Price: 1.702 EUR 2.65% Market Closed
Market Cap: 233.1m EUR

Operating Margin
DBV Technologies SA

-2 806%
Current
-1 527%
Average
-5.1%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 806%
=
Operating Profit
-116.5m
/
Revenue
4.2m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
FR
DBV Technologies SA
PAR:DBV
233.1m EUR
-2 806%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
336.1B USD
30%
US
Cyclo Therapeutics Inc
NASDAQ:CYTH
325.9B USD
-2 834%
US
Amgen Inc
NASDAQ:AMGN
164.8B USD
25%
US
Gilead Sciences Inc
NASDAQ:GILD
144.7B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
120.7B USD
38%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
129.7B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
60.9B USD
29%
US
Seagen Inc
F:SGT
39.3B EUR
-33%

DBV Technologies SA
Glance View

Market Cap
233.1m EUR
Industry
Biotechnology

DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The company is headquartered in Montrouge, Ile-De-France. The company went IPO on 2012-03-29. The firm's therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. The company dedicates its technology to treat patients, including infants and children, suffering from severe food allergies, for whom safety is paramount, since the introduction of the offending allergen into their bloodstream can cause severe or life-threatening allergic reactions, such as anaphylactic shock. The firm's product portfolio for allergy treatments consists of Viaskin Peanut, Viaskin Milk and Viaskin Egg. The firm operates one subsidiary DBV Technologies Inc. in the United States.

DBV Intrinsic Value
0.836 EUR
Overvaluation 51%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-2 806%
=
Operating Profit
-116.5m
/
Revenue
4.2m
What is the Operating Margin of DBV Technologies SA?

Based on DBV Technologies SA's most recent financial statements, the company has Operating Margin of -2 806%.

Back to Top